Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some mechanistic and general safety statements align with label language (e.g., IL-17A binding/inhibiting IL-17 receptor interaction; increased infection risk). Several detailed mechanistic claims about specific immune cell recruitment/cytokine decreases and “reduces overall inflammatory response” are not supported by the provided label excerpts, and the response omits key boxed warning-equivalent safety content that is relevant (TB evaluation, live vaccine avoidance, hypersensitivity specifics).
Category Scores
Accurate Statements
Cosentyx (secukinumab) targets and blocks the activity of interleukin-17A (IL-17A).
12.1 Mechanism of Action: secukinumab selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor.
Blocking IL-17A disrupts the IL-17A signaling pathway.
12.1 Mechanism of Action (inhibits IL-17A interaction with IL-17 receptor). The provided excerpts do not explicitly say “disrupts the signaling pathway,” but the idea is consistent with receptor interaction inhibition.
Cosentyx provides treatment for psoriasis.
1 Indications and Usage: moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older.
Cosentyx provides treatment for psoriatic arthritis.
1 Indications and Usage: active psoriatic arthritis in adults and pediatric patients 2 years of age and older.
Cosentyx provides treatment for ankylosing spondylitis.
1 Indications and Usage: active ankylosing spondylitis in adults and pediatric patients 12 years of age and older.
Potential side effects of Cosentyx include upper respiratory tract infections.
5.1 Infections and 6 Adverse Reactions: infections reported more frequently (specific infection type not provided in excerpts).
Unsupported Statements
Cosentyx prevents IL-17A from interacting with its receptor on the surface of immune cells.
12.1 states inhibition of IL-17A interaction with the IL-17 receptor, but the provided excerpts do not specify “on the surface of immune cells.”
The IL-17A signaling pathway is essential for the recruitment and activation of immune cells in inflamed tissue.
Not supported in the provided label excerpts.
Cosentyx reduces the recruitment of immune cells, such as neutrophils and T cells, to the site of inflammation.
Not supported. The label excerpt 12.2 mentions reduction of epidermal neutrophils in exploratory trials, but does not claim reduction of T-cell recruitment or “site of inflammation” recruitment broadly.
Cosentyx decreases the production of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β.
Not supported in the provided label excerpts.
Cosentyx modulates the activity of immune cells such as macrophages and dendritic cells.
Not supported in the provided label excerpts.
By blocking IL-17A, Cosentyx reduces the production of pro-inflammatory cytokines by macrophages.
Not supported.
By blocking IL-17A, Cosentyx reduces the production of pro-inflammatory cytokines by dendritic cells.
Not supported.
Cosentyx reduces the proliferation and activation of T cells.
Not supported.
Reducing T-cell proliferation and activation leads to a decrease in the production of pro-inflammatory cytokines.
Not supported.
Reducing T-cell proliferation and activation leads to a reduction in the overall inflammatory response.
Not supported.
Cosentyx reduces the production of pro-inflammatory cytokines by macrophages.
Not supported.
Cosentyx reduces the overall inflammatory response.
Not supported.
Cosentyx reduces the production of pro-inflammatory cytokines by dendritic cells.
Not supported.
Cosentyx decreases the overall inflammatory response.
Not supported.
Cosentyx reduces inflammation and modulates the activity of immune cells by blocking IL-17A.
General statement partially consistent with mechanism (12.1) but not supported in the provided excerpts as a specific immunomodulatory mechanism.
Potential side effects of Cosentyx include fatigue.
The provided label excerpts do not mention fatigue as an adverse reaction.
Contradictions
Important Omissions
Key safety pre-treatment evaluation and vaccination guidance: evaluate for active/latent TB, avoid initiation with active TB and initiate latent TB treatment; complete age-appropriate vaccinations prior to initiation and avoid live vaccines during treatment.
Importance:
High
Specific contraindication: prior serious hypersensitivity reaction to secukinumab or excipients.
Importance:
Moderate
Administration constraints and route: subcutaneous pens/syringes are for subcutaneous use only; solution in vials is for IV use in adults; pediatric patients should not self-administer; caregiver administration after training.
Importance:
Moderate
Any labeled dosage regimen details (loading dose schedules, weight-based pediatric dosing, or adjustments for inadequate response in specific indications).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several mechanistic assertions are unsupported by the provided label excerpts, and the response lists side effects without grounding in labeled adverse reaction details (e.g., fatigue not supported). It also omits prominent label safety requirements (TB evaluation/avoidance; live vaccine avoidance; immunization completion).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple detailed mechanistic and cytokine/cell-recruitment claims are not supported by the provided label excerpts, and key labeled safety/administration requirements are omitted.
Suggested Improvement
Limit mechanism statements to what the label excerpt supports (IL-17A binding and inhibition of IL-17A/IL-17 receptor interaction). For safety, include label-required TB evaluation and live vaccine avoidance/immunization guidance, and avoid listing adverse effects not present in the provided label excerpts (e.g., remove fatigue unless supported).